A Phase 3 interventional study of SHR-A1811 Injection and SHR-A1811 Injection ; Pertuzumab Injection in HER2-PositiveRecurrent or Metastatic Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing trastuzumab rezetecan in Breast Neoplasms — 45 open to participants now, 51 under way, 9 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.
Among the 52 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 9 that started in 2023, is one of 9 in phase 3, reaches primary completion later than 10 of the 50 other live ones, and was the 11th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →45 of the 52 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18–75 · Women only
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+ · Women only
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 41 · Phase 3 9 · Phase 4 1
First in 2022; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 868 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 106 across the 52 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 52 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 18 open now, 27 under way, 12 of them phase 3. Of 17 finished, 0 (0%) have results posted.
Among the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by enrollment, is one of 7 that started in 2023, is one of 20 in phase 3, reaches primary completion later than 7 of the 26 other live ones, and was the 32nd registered.
Jiangsu HengRui Medicine Co., Ltd.’s Breast Neoplasms studies by the year they started, since 2011.
5 of the studies testing trastuzumab rezetecan in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05424835Phase 3Jiangsu HengRui Medicine Co., Ltd.A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | 2026-12-31 |
| NCT07416253Henan Cancer HospitalTrastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer | 2027-03 |
| NCT07305246First Hospital of China Medical UniversityClinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer | 2027-03 |
| NCT06975462Wuhan Union Hospital, ChinaA Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases | 2027-06-01 |
| NCT07528898Hebei Medical University Fourth HospitalNeoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 52 studies testing trastuzumab rezetecan in Breast Neoplasms, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 53 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-A1811 Injection
Drug: SHR-A1811 Injection ; Pertuzumab Injection
Drug: Trastuzumab Injection;Pertuzumab Injection ; Docetaxel Injection
SHR-A1811 Injection
SHR-A1811 Injection ; Pertuzumab Injection
Trastuzumab Injection;Pertuzumab Injection ; Docetaxel Injection
This study also gives Trastuzumab, Pertuzumab. No intervention listed here names it: that was found by reading the record.
Progression Free Survival by Blinded Independent Central Review
Time frame: from first dose to disease progression, or death, whichever comes first, up to 3 years
Progression Free Survival by investigators
Time frame: from first dose to disease progression, or death, whichever comes first, up to 3 years
Overall Survival
Time frame: from first dose to death, up to 6 years
Objective Response Rate
Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years
Duration of response
Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years
AE
Time frame: from Day1 to 40 or 90 days after last dose
Incidence and severity of serious adverse events (SAE)
Time frame: from Day1 to 40 or 90 days after last dose
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Jul 2026, 32 months.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab rezetecan
Jiangsu HengRui Medicine Co., Ltd. →